唾液酸化Lewis X和半乳糖凝集素-3表达与甲状腺乳头状癌浸润转移的关系唾液酸化Lewis X和半乳糖凝集素-3表达与甲状腺乳头状癌浸润转移的关系.pdfVIP

下载本文档

5
0
约1.77万字
约 7页
2018-01-27 发布于贵州
举报
版权申诉

唾液酸化Lewis X和半乳糖凝集素-3表达与甲状腺乳头状癌浸润转移的关系唾液酸化Lewis X和半乳糖凝集素-3表达与甲状腺乳头状癌浸润转移的关系.pdf

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

唾液酸化Lewis X和半乳糖凝集素-3表达与甲状腺乳头状癌浸润转移的关系唾液酸化Lewis X和半乳糖凝集素-3表达与甲状腺乳头状癌浸润转移的关系

Asian Case Reports in Oncology 亚洲肿瘤科病例研究, 2017, 6(4), 33-39 Published Online October 2017 in Hans. /journal/acrpo /10.12677/acrpo.2017.64006 Expression of Sialyl Lewis X and Galectin-3 in Papillary Thyroid Carcinoma and Their Relationships with Invasion and Metastasis Peizhong Shang, Runling Nan, Jin Wang, Ana Nie, Yanyan Li, Wei Zhang, Wei Hu, Huaping Gu st Department of General Surgery, The 251 Hospital of Chinese PLA, Zhangjiakou Hebei th th st Received: Aug. 10 , 2017; accepted: Aug. 24 , 2017; published: Aug. 31 , 2017 Abstract Objective: To investigate the expression of sialyl Lewis X (SLeX) and Galectin-3 in papillary thyroid carcinoma and their relationships with the potential of invasion and metastasis. Methods: The ex- pression of SLeX and Galectin-3 in 164 cases of papillary thyroid carcinoma and 30 cases of pa- ra-tumorous tissue were studied by EliVisionTM plus two-step immunohistochemical method. Re- sults: The positive rates of SLeX and Galectin-3 in papillary thyroid carcinoma were 70.7% and 92.1%; those in para-tumorous tissue were 6.7% and 20.0%. Both in papillary thyroid carcinoma were significantly higher than those in para-tumorous tissue (P 0.05). The positive rates of SLeX and Galectin-3 in the patients with tumor invasion were 84.8% and 98.0%; those in the patients without tumor invasion were 49.2% and 83.1%. Both in the patients with tumor invasion were significantly higher than those in the patients without tumor invasion (P 0.05). The positive rates of SLeX and Galectin-3 in the patients with lymphatic metastasis were 89.2% and 96.8%;